Zenith Drugs– Are you looking for Zenith Drugs IPO GMP / Grey Market Premium and Kostak rate? You are at the right place, here you will get the latest Zenith Drugs IPO GMP live.
The public issue of Zenith Drugs will open on February 19, 2024 and remain open until February 22,2024 for bidding. It has set the price band at approximately approximately ₹75 to ₹79 per equity share and expects to raise ₹40.68 crore.
Ahead of Zenith Drugs opening date, grey market indicators are pointing to positive developments.
Zenith Drugs IPO GMP
Zenith Drugs Grey Market Premium (GMP) is currently at ₹35 , indicating the demand for the company's shares in the unofficial market.
Zenith Drugs IPO price band
The price band for Zenith Drugs initial public offering (IPO) has been set at ₹75 to ₹79 per equity share, offering potential investors a range within which they can place their bids.
Zenith Drugs IPO date
Starting from February 19, 2024, the IPO will be open for bidders to participate, and it will remain open until February 22, 2024, providing a limited window for interested parties to take part in the offering.
Zenith Drugs IPO size
With an ambitious goal of raising ₹40.68 Crores, Zenith Drugs is poised to make a significant impact in the financial markets through its IPO.
Zenith Drugs IPO lot size
Investors can apply for the IPO in lots, with each lot comprising 1600 shares, allowing them to tailor their investment based on their financial capacity and strategic objectives.
Zenith Drugs IPO application limit
The application limit for the IPO is set at a minimum of 1 lot for bidders, while retail investors have the opportunity to apply for up to 1 lots, offering flexibility in participation.
Zenith Drugs IPO allotment date
The tentative schedule for the allotment of Zenith Drugs IPO shares is February 23, 2024, providing a timeline for successful bidders to receive their allocated shares.
Zenith Drugs IPO listing
Zenith Drugs aims to list its shares on February 27, 2024, subject to market conditions, with plans to list on both the BSE and NSE, signaling a significant milestone for the company.
Zenith Drugs IPO registrar
Bigshare Services Pvt Ltd has been entrusted with the crucial role of serving as the registrar for Zenith Drugs, ensuring a smooth and efficient process for all stakeholders involved.
Investors and market analysts are closely monitoring the developments surrounding Zenith Drugs IPO, as it presents an opportunity to gauge the market's response to the company's offering. The subscription data and final oversubscription figures will provide valuable insights into the demand for AIK Pipes And Polymers's shares and the overall investor sentiment.
Zenith Drugs IPO is generating considerable interest due to the company's strong presence in the engineering and design services sector, as well as its diverse client base spanning various industries. Additionally, the IPO's performance will be indicative of investor confidence in the broader economic outlook and the attractiveness of the Indian capital markets.
As the IPO progresses through its various stages, prospective investors will closely analyze factors such as the company's financial performance, growth prospects, and competitive positioning to make informed decisions about participating in the offering. This heightened interest is expected to contribute to robust trading activity following the listing of Zenith Drugs shares.
The successful execution of Zenith Drugs IPO is anticipated to further bolster the company's financial position and provide funds for strategic initiatives, expansion plans, and potential acquisitions. Moreover, it will offer an opportunity for retail investors, institutional investors, and other market participants to gain exposure to a prominent player in the engineering and design services sector.
Overall, Zenith Drugs IPO is poised to make a significant impact on the Indian markets, and its outcome will be closely observed as a barometer of investor confidence and market dynamics.